Steven Holroyd, MD
Psychiatry · Reno, NVNPI 1871557942
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 28.9% of the total.
Across 148 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$737
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$351
- Johnson & Johnson$338
- Otsuka America Pharmaceutical, Inc.$298
- Lundbeck LLC$246
- Indivior Inc.$138
- plus $444 from 7 others
What the payments were for
- Food & beverage$2,54099%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $737 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $351 |
| Johnson & Johnson | 17 | $338 |
| Otsuka America Pharmaceutical, Inc. | 18 | $298 |
| Lundbeck LLC | 17 | $246 |
| Indivior Inc. | 9 | $138 |
| Teva Pharmaceuticals USA, Inc. | 7 | $136 |
| Vanda Pharmaceuticals Inc. | 5 | $76 |
| Alkermes, Inc. | 4 | $74 |
| Neurocrine Biosciences, Inc. | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| Eisai Inc. | 2 | $28 |
| Neuronetics, Inc. | 1 | $13 |
How this compares
$2,553 in reported general payments places this provider in the 75th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $461 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $412 |
| Alprazolam ErAlprazolam | 15 | $334 |
| Fluoxetine Hcl | 18 | $244 |
| Mirtazapine | 11 | $160 |
| Clonazepam | 19 | $81 |
| Zolpidem Tartrate | 23 | $67 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Reno
- Philip MalinasReno$111K
- Brian KirkpatrickReno$18K
- Nickolas CulpepperReno$8K
- Philip RichReno$6K
- Meekile MasonReno$6K
- Geraldine SteinagelReno$4K
- Kathleen StollReno$3K
- Jayleen ChenReno$2K
- Thomas BittkerReno$2K
- Jelena KunovacLas Vegas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.